Thailand In-Vitro Diagnostics Market: Growth Drivers, Trends, Challenges, and Opportunities by 2030

Thailand In-Vitro Diagnostics Market Overview

In-vitro diagnostics (IVD) refers to a variety of medical tests that are conducted on samples taken from the human body, such as blood, tissues, or other bodily fluids, to diagnose diseases, monitor therapies, and assess general health conditions. These tests are crucial in providing early detection of diseases and enabling timely interventions, ultimately leading to improved health outcomes.

According to Next Move Strategy Consulting, the Thailand In-Vitro Diagnostics Market is projected to grow at a compound annual growth rate (CAGR) of 6%, reaching USD 2 billion by 2030.Thailand’s growing healthcare sector, combined with advancements in diagnostic technology, is making IVD a crucial component in the country’s health infrastructure. The market is expected to expand due to factors like the increasing prevalence of non-communicable diseases, the aging population, and technological advancements in diagnostics.

Click Here For Your FREE Sample!

Market Dynamics Driving Growth

1. Rising Prevalence of Non-Communicable Diseases
   Non-communicable diseases (NCDs), including cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases, are becoming more prevalent in Thailand. According to the World Health Organization (WHO), NCDs account for around 74% of deaths in the country, amounting to approximately 400,000 fatalities annually. This alarming rise in NCDs is leading to a greater demand for advanced diagnostic technologies, including IVD, to ensure early disease detection, monitoring, and effective treatment strategies.
2. Increasing Aging Population
   Thailand is experiencing a rapid demographic shift, with a rising aging population. Approximately 20% of the population is currently over 60 years of age, and this percentage is expected to rise to 30% by 2030. Aging populations are more susceptible to a wide range of health conditions, from chronic diseases to age-related ailments. As a result, there is a growing demand for early-stage diagnostic technologies that can detect and treat such conditions before they become severe. The rise of in-vitro diagnostics is critical in offering precise diagnostics and enabling personalized healthcare services for the elderly.
3. Technological Advancements and Innovation
   Technological advancements in the IVD industry have led to the development of highly efficient diagnostic tools and methods. These include immunoassays, molecular diagnostics, clinical chemistry, haematology, and microbiology techniques. The adoption of cutting-edge IVD technologies such as Polymerase Chain Reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and chemiluminescence immunoassay (CLIA) are poised to enhance the accuracy and speed of disease diagnosis, further fuelling market growth.

Read the Full News

Segments of Thailand’s IVD Market

1. By Type The market is segmented based on product types, including reagents, instruments, and software & services. Among these, reagents dominate the market as they are integral in facilitating numerous diagnostic tests. Instruments, including diagnostic machines and laboratory equipment, hold a significant share as they are essential for conducting various diagnostic procedures. Software & services also contribute notably, especially with the increasing shift toward data-driven healthcare solutions that integrate diagnostics with treatment management.
2. By Technique The techniques used in in-vitro diagnostics include:
   • Immunodiagnostics: Techniques like ELISA, rapid tests, and chemiluminescence immunoassay (CLIA) that are used for detecting infectious diseases and monitoring therapeutic responses.
   • Hematology: Used to analyse blood components and diagnose conditions like anaemia or clotting disorders.
   • Molecular Diagnostics: Technologies like PCR, DNA diagnostics, and microarray to detect diseases at the genetic level.
   • Tissue Diagnostics: Used to assess and diagnose conditions related to tissues, including cancers.
   • Clinical Chemistry: Includes metabolic and organ function panels such as liver, renal, and thyroid function tests.
3. By Application The major applications of IVD in Thailand include:
   • Infectious Diseases: Diagnostic tests for HIV, Hepatitis, and COVID-19 are included.
   • Cancer: IVDs for early detection and monitoring of cancer treatment.
   • Cardiac Diseases: Tests for biomarkers related to heart disease such as troponin and B-type natriuretic peptide (BNP).
   • Immune System Disorders: Diagnostics for autoimmune diseases and immune deficiencies.
   • Nephrological Diseases: Testing related to kidney function and disorders.
   • Gastrointestinal Diseases: Diagnostics for diseases like irritable bowel syndrome (IBS), celiac disease, and gastrointestinal cancers.
4. By End User The end users in the IVD market include:
   • Standalone Laboratories: Dedicated diagnostic centers.
   • Hospitals: The primary healthcare facilities where IVD is used extensively.
   • Academics and Medical Schools: Research institutions that use IVD technologies for education and research.
   • Point-of-Care Testing (POCT): Rapid diagnostic tests administered outside of traditional laboratories, providing quick results in various settings like ambulances and emergency rooms.

Challenges Impacting the Market

Despite significant growth prospects, the Thailand IVD market faces several challenges that could hinder its expansion:

1. High Research and Development Costs
   The process of developing and bringing IVD products to market is costly. Extensive clinical trials, regulatory approvals, and product testing demand significant investment. This financial burden can slow down the introduction of new products and limit market competition.
2. Regulatory Hurdles
   The regulatory environment for IVD products is complex, requiring manufacturers to meet stringent standards set by authorities like the FDA and local regulatory bodies. The approval process is time-consuming and costly, deterring some companies from entering the market.
3. Limited Access to Advanced Technologies in Rural Areas
   While urban centers in Thailand benefit from advanced healthcare infrastructure, rural areas may not have access to state-of-the-art diagnostic tools. This geographic disparity could slow down overall market growth and limit the adoption of IVD solutions nationwide.

Opportunities for Growth

1. Point-of-Care Testing (POCT)
   POCT is gaining traction as a rapidly growing segment within the IVD market. With its ability to deliver fast results at the patient’s bedside or in remote settings, POCT technologies are crucial in emergency care, ambulatory services, and rural healthcare. The integration of POCT with traditional laboratory testing is expected to improve diagnostic efficiency and patient outcomes significantly.
2. Increased Healthcare Expenditure
   Thailand’s healthcare sector is receiving more investment, driven by both the public and private sectors. The government’s commitment to healthcare development, alongside the increasing number of private healthcare providers, is likely to expand the accessibility and availability of IVD solutions across the country.
3. Telemedicine and Digital Health Integration
   The ongoing shift toward telemedicine and digital health solutions offers an exciting opportunity for IVD technologies. Telemedicine platforms can incorporate diagnostic tools for remote consultations, making healthcare more accessible to people across the country, especially in underserved regions.

Competitive Landscape

Key players in the Thailand in-vitro diagnostics market include global leaders such as:

• Roche Holding AG
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Siemens Healthineers AG
• bioMérieux SA
• Sysmex Corporation
• QIAGEN N.V.
• Illumina Inc.

These companies are focusing on expanding their product portfolios, improving diagnostic accuracy, and leveraging strategic collaborations to strengthen their market position.

Conclusion

The Thailand In-Vitro Diagnostics (IVD) market is on a promising growth trajectory, driven by factors such as the increasing prevalence of non-communicable diseases, a rapidly aging population, and ongoing advancements in diagnostic technologies. With a projected market value of USD 2 billion by 2030, the market is set to expand at a robust CAGR of 6% by 2030.

Key segments such as reagents, instruments, and software & services, along with techniques like immunodiagnostics, molecular diagnostics, and clinical chemistry, are at the forefront of this expansion. Additionally, the integration of point-of-care testing and the increasing adoption of digital health solutions present significant opportunities for market growth. However, challenges like high R&D costs, regulatory complexities, and regional disparities in healthcare access must be addressed to ensure the continued success of the IVD market in Thailand.

Overall, the Thailand IVD market holds substantial potential, and as the healthcare infrastructure evolves to meet the needs of an aging population and rising disease burden, the demand for advanced diagnostic solutions will continue to drive innovation and market expansion. For stakeholders, including healthcare providers, technology developers, and investors, the Thailand IVD market represents an exciting opportunity for growth and contribution to improving public health outcomes.